Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNYNASDAQ:NKLANASDAQ:QDEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$331.94+0.7%$293.35$205.87▼$333.70$43.00B0.23853,986 shs431,157 shsNKLANikola$0.18-28.7%$0.18$0.18▼$11.94$11.14M1.9710.25 million shs36.66 million shsQDELQuidelOrtho$30.170.0%$30.12$23.77▼$49.45$2.04B0.071.14 million shs999,310 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals+0.66%+4.30%+9.27%+40.81%+33.48%NKLANikola0.00%0.00%0.00%0.00%-97.75%QDELQuidelOrtho-0.05%+5.10%-0.41%+7.23%-2.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALNYAlnylam Pharmaceuticals4.3159 of 5 stars2.44.00.04.33.92.50.6NKLANikola1.096 of 5 stars3.10.00.00.00.60.00.6QDELQuidelOrtho4.3535 of 5 stars3.22.00.03.81.41.72.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNYAlnylam Pharmaceuticals 2.79Moderate Buy$340.002.43% UpsideNKLANikola 2.25Hold$6.003,178.69% UpsideQDELQuidelOrtho 2.43Hold$44.3346.97% UpsideCurrent Analyst Ratings BreakdownLatest NKLA, QDEL, and ALNY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025ALNYAlnylam PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$287.00 ➝ $333.006/26/2025ALNYAlnylam PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$320.00 ➝ $377.006/24/2025ALNYAlnylam PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$300.00 ➝ $360.006/12/2025ALNYAlnylam PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$330.00 ➝ $338.005/8/2025QDELQuidelOrthoUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$45.00 ➝ $29.005/8/2025QDELQuidelOrthoJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$44.005/2/2025ALNYAlnylam PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$331.00 ➝ $349.005/2/2025ALNYAlnylam PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$300.00 ➝ $325.004/21/2025QDELQuidelOrthoJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$38.00 ➝ $25.004/11/2025ALNYAlnylam PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$284.00 ➝ $268.004/9/2025ALNYAlnylam PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$320.00 ➝ $320.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNYAlnylam Pharmaceuticals$2.25B19.25N/AN/A$0.52 per share638.35NKLANikola$75.53M0.15N/AN/A$16.24 per share0.01QDELQuidelOrtho$2.78B0.73$35.49 per share0.85$44.38 per share0.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNYAlnylam Pharmaceuticals-$278.16M-$2.09N/A372.97N/A-11.49%-510.31%-6.48%7/30/2025 (Estimated)NKLANikola-$966.28M-$14.26N/A∞N/A-840.44%-95.73%-46.23%8/7/2025 (Estimated)QDELQuidelOrtho-$2.05B-$4.97N/A9.40N/A-12.07%4.71%2.21%7/30/2025 (Estimated)Latest NKLA, QDEL, and ALNY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025QDELQuidelOrtho$0.0122N/AN/AN/A$612.36 millionN/A5/7/2025Q1 2025QDELQuidelOrtho$0.61$0.74+$0.13-$0.19$694.97 million$692.80 million5/1/2025Q1 2025ALNYAlnylam Pharmaceuticals-$0.37-$0.44-$0.07-$0.44$584.32 million$594.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNYAlnylam PharmaceuticalsN/AN/AN/AN/AN/ANKLANikolaN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNYAlnylam Pharmaceuticals8.883.042.98NKLANikola0.711.170.94QDELQuidelOrtho0.701.200.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNYAlnylam Pharmaceuticals92.97%NKLANikola37.38%QDELQuidelOrtho99.00%Insider OwnershipCompanyInsider OwnershipALNYAlnylam Pharmaceuticals1.50%NKLANikola0.74%QDELQuidelOrtho0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNYAlnylam Pharmaceuticals2,230130.39 million128.43 millionOptionableNKLANikola1,50060.87 million60.42 millionOptionableQDELQuidelOrtho7,00067.63 million67.09 millionOptionableNKLA, QDEL, and ALNY HeadlinesRecent News About These CompaniesWealth Enhancement Advisory Services LLC Raises Position in QuidelOrtho Corporation (NASDAQ:QDEL)June 29, 2025 | marketbeat.comBrokerages Set QuidelOrtho Corporation (NASDAQ:QDEL) Target Price at $44.33June 27, 2025 | americanbankingnews.comQuidelOrtho (NASDAQ:QDEL) Releases FY 2025 Earnings GuidanceJune 26, 2025 | marketbeat.comReasons to Retain QuidelOrtho Stock in Your Portfolio for NowJune 24, 2025 | zacks.comQuidelOrtho Corporation (NASDAQ:QDEL) Receives Average Recommendation of "Hold" from BrokeragesJune 24, 2025 | marketbeat.comWhat Makes QuidelOrtho (QDEL) a New Buy StockJune 18, 2025 | zacks.comWhy QuidelOrtho (QDEL) is a Top Growth Stock for the Long-TermJune 18, 2025 | zacks.comShould Value Investors Buy QuidelOrtho (QDEL) Stock?June 18, 2025 | zacks.com3 Reasons to Sell QDEL and 1 Stock to Buy InsteadJune 16, 2025 | msn.comAssenagon Asset Management S.A. Invests $10.92 Million in QuidelOrtho Co. (NASDAQ:QDEL)June 14, 2025 | marketbeat.comQuidelOrtho Co. (NASDAQ:QDEL) Shares Acquired by GAMMA Investing LLCJune 13, 2025 | marketbeat.comQDEL Q1 Earnings Call: Cost Savings and Tariff Mitigation Anchor 2025 OutlookJune 11, 2025 | msn.comPallas Capital Advisors LLC Has $1.29 Million Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)June 11, 2025 | marketbeat.comQuidelOrtho Co. (NASDAQ:QDEL) Stock Position Lowered by Wedge Capital Management L L P NCJune 10, 2025 | marketbeat.comQuidelOrtho Corp (QDEL) Trading 4% Higher on Jun 9June 9, 2025 | gurufocus.comMerit Financial Group LLC Acquires 15,304 Shares of QuidelOrtho Co. (NASDAQ:QDEL)June 9, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Has $1.52 Million Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)June 7, 2025 | marketbeat.comQuidelOrtho (NASDAQ:QDEL) Raised to Buy at Wall Street ZenJune 6, 2025 | marketbeat.comQuidelOrtho Co. (NASDAQ:QDEL) Stake Increased by California State Teachers Retirement SystemJune 6, 2025 | marketbeat.comBank of America Corp DE Trims Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL)June 6, 2025 | marketbeat.comQuidelOrtho Declares that its Molecular Diagnostics Approach will be RefocusedJune 4, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNKLA, QDEL, and ALNY Company DescriptionsAlnylam Pharmaceuticals NASDAQ:ALNY$331.94 +2.17 (+0.66%) Closing price 07/3/2025 03:39 PM EasternExtended Trading$331.94 0.00 (0.00%) As of 07/3/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Nikola NASDAQ:NKLA$0.18 -0.07 (-28.74%) Closing price 02/25/2025Extended Trading$0.18 0.00 (0.00%) As of 02/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions in the United States and internationally. The company operates in truck and energy units. It commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. In addition, it develops a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. Further, its products include Nikola Tre Class 8 truck and the Nikola's Class 8 FCEV. Additionally, the company assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.QuidelOrtho NASDAQ:QDEL$30.16 -0.02 (-0.05%) Closing price 07/3/2025 01:23 PM EasternExtended Trading$30.16 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
